Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Biochimica et Biophysica Acta

• Publication date

  2010-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bbcan.2009.11.004PMID 19961901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

  2010cited by this paper
• Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

  2009cited by this paper
• Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

  2009cited by this paper
• Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling.

  2009cited by this paper
• A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC).

  2009cited by this paper
• Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC).

  2009cited by this paper
• Oxaliplatin enhances TRAIL‐induced apoptosis in gastric cancer cells by CBL‐regulated death receptor redistribution in lipid rafts

  2009cited by this paper
• TRAIL receptor signalling and modulation: Are we on the right TRAIL?

  2009cited by this paper
• Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC).

  2009cited by this paper
• Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib

  2009cited by this paper
• Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling.

  2009cited by this paper
• Caspase-8 in cancer biology and therapy.

  2009cited by this paper
• Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

  2009cited by this paper
• A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results.

  2009cited by this paper
• Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.

  2009cited by this paper
• The Death Domain of FADD Is Essential for Embryogenesis, Lymphocyte Development, and Proliferation*

  2009cited by this paper
• IAP-targeted therapies for cancer

  2008cited by this paper
• FLIP as an Anti-Cancer Therapeutic Target

  2008cited by this paper
• TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5

  2008cited by this paper
• MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer

  2008cited by this paper
• Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

  2008cited by this paper
• DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design*

  2008cited by this paper
• Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism

  2008cited by this paper
• The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases

  2008cited by this paper
• Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway

  2008cited by this paper
• TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.

  2008cited by this paper
• Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.

  2008cited by this paper
• Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

  2008cited by this paper
• LBY135, a novel anti‐DR5 agonistic antibody induces tumor cell–specific cytotoxic activity in human colon tumor cell lines and xenografts

  2008cited by this paper
• Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL

  2008cited by this paper
• Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival

  2008cited by this paper
• Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.

  2008cited by this paper
• A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

  2008cited by this paper
• Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level

  2008cited by this paper
• Targeting TRAIL death receptors.

  2008cited by this paper
• Identification of an antiapoptotic protein complex at death receptors

  2008cited by this paper
• A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

  2008cited by this paper
• TRAIL signalling: decisions between life and death.

  2007cited by this paper
• P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes.

  2007cited by this paper
• Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.

  2007cited by this paper
• Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

  2007cited by this paper
• Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.

  2007cited by this paper
• Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells.

  2007cited by this paper
• TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window

  2007cited by this paper
• Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.

  2007cited by this paper
• The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.

  2007cited by this paper
• TRAIL therapy in non–small cell lung cancer cells: sensitization to death receptor–mediated apoptosis by proteasome inhibitor bortezomib

  2007cited by this paper
• A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI

  2007cited by this paper
• Receptor-mediated Endocytosis Is Not Required for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis*

  2007cited by this paper
• A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer

  2007cited by this paper
• Bortezomib Sensitizes Non–Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2

  2007cited by this paper
• Bortezomib Sensitizes Human Astrocytoma Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

  2007cited by this paper
• Life and death in peripheral T cells

  2007cited by this paper
• First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors

  2007cited by this paper
• Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts

  2007cited by this paper
• LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization

  2007cited by this paper
• TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL‐R1 whereas cross‐linked agonistic TRAIL‐R2 antibodies facilitate signalling via TRAIL‐R2

  2007cited by this paper
• Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

  2007cited by this paper
• Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

  2007cited by this paper
• CCAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction and Ubiquitin/Proteasome-Mediated Cellular FLICE-Inhibitory Protein Down-Regulation Contribute to Enhancement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Dimethyl-Celecoxib in H

  2007cited by this paper
• Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

  2007cited by this paper
• MADD/DENN Splice Variant of the IG20 Gene Is a Negative Regulator of Caspase-8 Activation

  2007cited by this paper
• The promise of TRAIL—potential and risks of a novel anticancer therapy

  2007cited by this paper
• Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway.

  2007cited by this paper
• Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding*

  2007cited by this paper
• Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms

  2007cited by this paper
• Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

  2006cited by this paper
• Palmitoylation of Ligands, Receptors, and Intracellular Signaling Molecules

  2006cited by this paper
• Proteasome inhibitor MG132 sensitizes HPV‐positive human cervical cancer cells to rhTRAIL‐induced apoptosis

  2006cited by this paper
• Death-receptor activation halts clathrin-dependent endocytosis

  2006cited by this paper
• Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo

  2006cited by this paper
• Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer

  2006cited by this paper
• The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL

  2006cited by this paper
• Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.

  2006cited by this paper
• Src kinase phosphorylates Caspase‐8 on Tyr380: a novel mechanism of apoptosis suppression

  2006cited by this paper
• A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer.

  2006cited by this paper
• Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2

  2006cited by this paper
• Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.

  2006cited by this paper
• TRAIL-Induced Apoptosis in U-1242 MG Glioma Cells

  2006cited by this paper
• Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.

  2006cited by this paper
• Nitrosylcobalamin Promotes Cell Death via S Nitrosylation of Apo2L/TRAIL Receptor DR4

  2006cited by this paper
• Rafts defined: a report on the Keystone symposium on lipid rafts and cell function Published, JLR Papers in Press, April 27, 2006.

  2006cited by this paper
• TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis

  2006cited by this paper
• Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy.

  2006cited by this paper
• MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival

  2006cited by this paper
• Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL

  2006cited by this paper
• Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.

  2006cited by this paper
• Cisplatin‐dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF‐related apoptosis‐inducing ligand against esophageal squamous cell carcinoma

  2006cited by this paper
• Lipid rafts: now you see them, now you don't

  2006cited by this paper
• The clinical trail of TRAIL.

  2006cited by this paper
• The Proteasome Is Required for Rapid Initiation of Death Receptor-Induced Apoptosis

  2006cited by this paper
• Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death

  2005cited by this paper
• Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.

  2005cited by this paper
• Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.

  2005cited by this paper
• Rapid Turnover of c-FLIPshort Is Determined by Its Unique C-terminal Tail*

  2005cited by this paper
• Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity.

  2005cited by this paper
• Promoting apoptosis as a strategy for cancer drug discovery

  2005cited by this paper
• Apoptosis of colon cancer: Comparison with Ki-67 proliferative activity and expression of p53

  2005cited by this paper
• TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.

  2005cited by this paper
• Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines

  2005cited by this paper

• Effect of Quizartinib on the Resistance of Acute Myeloid Leukemia Cells with FLT3-ITD-Positive and FLT3-ITD-Negative Phenotypes to the TRAIL-Induced Apoptosis

  2026cites this paper
• The Combination of PF-543 and TRAIL Effectively Induces Apoptotic Cell Death and Inhibits Stem Cell-Like Properties Through the SPHK1/S1PR1/STAT3 Pathway in TRAIL-Resistant Colorectal Cancer Cells

  2025cites this paper
• The role of tumor necrosis factor receptor superfamily in cancer: insights into oncogenesis, progression, and therapeutic strategies

  2025cites this paper
• Mechanistic insights of neuronal death and neuroprotective therapeutic approaches in stroke

  2025cites this paper
• The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models

  2025cites this paper
• The ubiquitin ligase NKLAM promotes apoptosis and suppression of cell growth

  2025cites this paper
• Evolution of Apoptotic Signaling Pathways Within Lophotrochozoans

  2024cites this paper
• The Association of Death Receptors and TGF-β1 Expression in Urothelial Bladder Cancer and Their Prognostic Significance

  2024cites this paper
• Core Fucosylation Mediated by the FucT-8 Enzyme Affects TRAIL-Induced Apoptosis and Sensitivity to Chemotherapy in Human SW480 and SW620 Colorectal Cancer Cells

  2023cites this paper
• PARP inhibitors enhance reovirus-mediated cell killing through the death-inducing signaling complex (DISC) with an associated NF-κB-regulated immune response

  2023cites this paper
• Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5.

  2023cites this paper
• Carotenoids for lung cancer chemoprevention and chemotherapy: Promises and controversies.

  2023cites this paper
• Apoptosis in megakaryocytes: Safeguard and threat for thrombopoiesis

  2023cites this paper
• RTA dh404 Induces Cell Cycle Arrest, Apoptosis, and Autophagy in Glioblastoma Cells

  2023cites this paper
• Insight into the Pathophysiology of Myocardial Infarction

  2022cites this paper
• Overcoming TRAIL Resistance for Glioblastoma Treatment

  2021cites this paper
• Two-level modeling approach to identify the regulatory dynamics capturing drug response heterogeneity in single-cells

  2021cites this paper
• Intrinsic and extrinsic apoptosis responses in leukaemia cells following daunorubicin treatment

  2021cites this paper
• Concentration-Independent Multivalent Targeting of Cancer Cells by Genetically Encoded Core-Crosslinked Elastin/Resilin-like Polypeptide Micelles.

  2021cites this paper
• Cellular and molecular mechanisms of liver regeneration: Proliferation, growth, death and protection of hepatocytes.

  2020cites this paper
• Mesenchymal epithelial transition factor regulates tumor necrosis factor-related apoptotic induction ligand resistance in hepatocellular carcinoma cells through down-regulation of cyclin B1.

  2020cites this paper
• Deoxypodophyllotoxin, a Lignan from Anthriscus sylvestris, Induces Apoptosis and Cell Cycle Arrest by Inhibiting the EGFR Signaling Pathways in Esophageal Squamous Cell Carcinoma Cells

  2020cites this paper
• Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib

  2020cites this paper
• Death receptor 5 is activated by fucosylation in colon cancer cells

  2019cites this paper
• Ursolic acid regulates apoptosis and autophagy of gastric cancer cell line MGC- 803 and its mechanism

  2019influential citation
• Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines

  2019cites this paper
• Inhibition of BAP31 expression inhibits cervical cancer progression by suppressing metastasis and inducing intrinsic and extrinsic apoptosis.

  2019cites this paper
• Antitumor Effect of Periplocin in TRAIL‐Resistant gastric cancer cells via upregulation of death receptor through activating ERK1/2‐EGR1 pathway

  2019cites this paper
• University of Groningen Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling

  2019cites this paper
• Post-translational modification of the death receptor complex as a potential therapeutic target in cancer

  2019cites this paper
• Effects of apoptosis on liver aging

  2019cites this paper
• Herpes Simplex Virus Type 1 Infection of the Central Nervous System: Insights Into Proposed Interrelationships With Neurodegenerative Disorders

  2019cites this paper
• Modulation of CD95-mediated signaling by post-translational modifications: towards understanding CD95 signaling networks

  2019cites this paper
• Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells

  2019cites this paper
• Interactive Multiresolution Visualization of Cellular Network Processes

  2019cites this paper
• Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy

  2019cites this paper
• La inactivación de Pim quinasas potencia la muerte celular mediada por el ligando de muerte trail en glioblastoma

  2019cites this paper
• Dianas terapeuticas en mieloma multiple: desregulación de mirnas y trail

  2019cites this paper
• Characterising heterogeneous TRAIL responsiveness and overcoming TRAIL resistance in multicellular tumour spheroids

  2018cites this paper
• ROLE OF TRAIL RECEPTORS ON CANCER

  2018cites this paper
• The combined effects or arsenic cadmium and mercury on hepatocarcinoma and neuroblastoma cells in vitro

  2018cites this paper
• LINC01170 promotes the progression of endometrial carcinoma by activating the AKT pathway.

  2018cites this paper
• Dominant Negative FADD/MORT1 Inhibits the Development of Intestinal Intraepithelial Lymphocytes With a Marked Defect on CD8αα+TCRγδ+ T Cells

  2018cites this paper
• Shear stress promotes anoikis resistance of cancer cells via caveolin‐1‐dependent extrinsic and intrinsic apoptotic pathways

  2018cites this paper
• 3-Bromopyruvate sensitizes human breast cancer cells to TRAIL-induced apoptosis via the phosphorylated AMPK-mediated upregulation of DR5

  2018cites this paper
• Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies

  2018cites this paper
• Carnosic acid and fisetin combination therapy enhances inhibition of lung cancer through apoptosis induction.

  2017cites this paper
• Chalcones Target the Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) Signaling Pathway for Cancer Chemoprevention

  2017cites this paper
• Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1

  2017cites this paper
• Hsp90 inhibitor sensitizes TRAIL-mediated apoptosis via chop-dependent DR5 upregulation in colon cancer cells.

  2017cites this paper
• University of Groningen Trail receptor-targeted therapy : strategies to enhance DR 4-and DR 5-induced apoptosis

  2017influential citation
• The suppression of apoptosis by α-herpesvirus

  2017cites this paper
• Fisetin inhibits liver cancer growth in a mouse model: Relation to dopamine receptor

  2017cites this paper
• Using natural products to promote caspase-8-dependent cancer cell death

  2017cites this paper
• The role of human phospholipid scramblases in apoptosis: An overview.

  2017cites this paper
• Identification and Characterisation of Novel Mechanisms that Regulate TRAIL-Receptor Signalling Complexes

  2017cites this paper
• Enhancement of death receptor-mediated apoptosis in multiple myeloma cells

  2017cites this paper
• Identification, characterization and bioactivity of tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand from Equus caballus

  2017cites this paper
• Hsp 90 inhibitor sensitizes TRAIL-mediated apoptosis via chop-dependent DR 5 upregulation in colon cancer cells

  2017cites this paper
• Terminalia Chebula provides protection against dual modes of necroptotic and apoptotic cell death upon death receptor ligation

  2016cites this paper
• Inhibition of autophagy sensitises cells to hydrogen peroxide-induced apoptosis: Protective effect of mild thermotolerance acquired at 40°C.

  2016cites this paper
• Structural Studies of the Mechanism by Which BCL-2 and Beclin Proteins Regulate Autophagy and Apoptosis

  2016cites this paper
• Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells after Treatment with Xanthohumol—A Natural Compound Present in Humulus lupulus L.

  2016cites this paper
• Crosstalk between Autophagy and Apoptosis: Potential and Emerging Therapeutic Targets for Cardiac Diseases

  2016cites this paper
• Insights into roles of the miR-1, -133 and -206 family in gastric cancer (Review).

  2016cites this paper
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) activates caspases in human prostate cancer cells through sigma 1 receptor.

  2016cites this paper
• Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents

  2016cites this paper
• New withanolides with TRAIL-sensitizing effect from Physalis pubescens L.

  2016cites this paper
• Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer

  2016cites this paper
• Activation of apoptosis signalling pathways by reactive oxygen species.

  2016cites this paper
• Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold

  2015cites this paper
• Improving therapeutic approaches for the treatment of Non-small Cell Lung Cancer using an ex-vivo explant culture system

  2015cites this paper
• A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death

  2015cites this paper
• Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2 – markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics

  2015cites this paper
• 5‐Fluorouracil preferentially sensitizes mutant KRAS non‐small cell lung carcinoma cells to TRAIL‐induced apoptosis

  2015influential citation
• A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression

  2015cites this paper
• � , �-�ih�dro���avone �nhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related Proteins

  2015cites this paper
• Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.

  2015cites this paper
• Furin‐Mediated Sequential Delivery of Anticancer Cytokine and Small‐Molecule Drug Shuttled by Graphene

  2015cites this paper
• The role of death-associated protein 3 in apoptosis, anoikis and human cancer

  2015cites this paper
• The Tumor Suppressor RASSF1A Links Inflammation and Cancer

  2015cites this paper
• HOOKING TRAIL-R2 TO ¿EDUCATE¿ IMMUNE SYSTEM TO RECOGNIZE CANCER CELLS

  2015cites this paper
• New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants.

  2015cites this paper
• Tissue Factor Noncoagulant Signaling: Mechanisms and Implications for Cell Migration and Apoptosis

  2015cites this paper
• Graph theoretic network analysis reveals protein pathways underlying cell death following neurotropic viral infection

  2015cites this paper
• Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis.

  2015cites this paper
• Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?

  2014cites this paper
• Switching Off Key Signaling Survival Molecules to Switch On the Resolution of Inflammation

  2014cites this paper
• Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL).

  2014cites this paper
• Modulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathways

  2014cites this paper
• The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer.

  2014cites this paper
• Autophagy and apoptosis: where do they meet?

  2014cites this paper
• Modulation of the Sensitivity of Jurkat T-Cells to Inhibition of Protein Synthesis by Tumor Necrosis Factor α-Related Apoptosis-Inducing Ligand

  2014cites this paper
• Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells

  2014cites this paper
• Trail receptor-targeted therapy : strategies to enhance DR4-and DR5-induced apoptosis

  2014cites this paper
• Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma

  2014cites this paper
• Trail receptor-targeted therapy : strategies to enhance DR4- and DR5-induced apoptosis

  2014influential citation
• Emodin Suppresses Hyperglycemia-Induced Proliferation and Fibronectin Expression in Mesangial Cells via Inhibiting cFLIP

  2014cites this paper
• The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells

  2014cites this paper
• Laminarin-induced apoptosis in human colon cancer LoVo cells

  2014cites this paper